Sendek Joel 4
4 · Spero Therapeutics, Inc. · Filed Jul 6, 2018
Insider Transaction Report
Form 4
Sendek Joel
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2018-07-05$5.90/sh+2,000$11,800→ 17,181 total - Sale
Common Stock
2018-07-05$17.50/sh−2,000$35,000→ 15,181 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-07-05−2,000→ 165,833 totalExercise: $5.90Exp: 2027-07-05→ Common Stock (2,000 underlying)
Footnotes (3)
- [F1]The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017.
- [F2]Amount includes 10,181 shares of common stock held by the Joel D. Sendek Retained Annuity Trust No. 1, of which the Reporting Person is a trustee.
- [F3]The shares underlying this option vested as to 25% on May 1, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.